Alexander disease

Lore & Background

Alexander disease was first identified in 1949 by W. Stewart Alexander, who treated a 15-month-old infant with megalencephaly, hydrocephaly, seizures, and developmental delays. Between 1949 and 1964, 15 more similar cases were observed, leading to the suggestion that these cases represented the same disease and that it be named after Alexander. The disease occurs in both males and females, with no ethnic, racial, geographic, or cultural/economic differences in its distribution.

Reader's Guide

Alexander disease is a progressive and often fatal leukodystrophy caused by mutations in the GFAP gene, inherited in an autosomal dominant manner, though most cases arise de novo. It is classified by age at onset into infantile, juvenile, and adult forms, or alternatively into Type I (onset before age 4) and Type II (onset after age 4). Symptoms vary widely but include developmental delays, seizures, macrocephaly, spasticity, and in adult forms, symptoms mimicking Parkinson's disease, multiple sclerosis, or psychiatric disorders. Diagnosis is made via MRI, genetic testing, or clinical symptoms. Prognosis is poor: infantile form patients usually die before age seven, with an average duration of about three years; juvenile form duration is about six years. Zilganersen (Zanvastro) was approved for medical use in the United States in September 2026. The disease is very rare, with an estimated prevalence of 1 in 2.7 million.

Did You Know?

• Alexander disease was first documented in 1949 by W. Stewart Alexander, who treated a 15-month-old infant.
• The disease is caused by mutations in the GFAP gene on chromosome 17q21, inherited in an autosomal dominant manner.
• Rosenthal fibers—abnormal clumps of protein in astrocytes—are a hallmark of Alexander disease.
• Zilganersen (Zanvastro) was approved for medical use in the United States in September 2026.

Clinical Presentation Across the Lifespan

Alexander disease manifests differently depending on when it first appears, and its symptoms span a wide spectrum of neurological and developmental disruption. In its most common infantile presentation, the condition typically emerges within the first two years of life, bringing with it delays in both mental and physical growth, a troubling regression of previously achieved milestones, an abnormal enlargement of the head, and recurrent seizures. The juvenile form, which surfaces between the second and thirteenth years, tends to produce excessive vomiting, struggles with swallowing and speech, deteriorating coordination, and a gradual loss of voluntary motor control. Adult-onset cases present a particularly diagnostic challenge because their symptoms can closely resemble those of Parkinson's disease, multiple sclerosis, or even a primary psychiatric condition. Researchers have further subdivided the disease into Type I, appearing before age four with limb stiffness, an enlarged brain, and difficulty gaining weight, and Type II, emerging after age four with scoliosis, speech impairment, and persistent vomiting. Some scholars have also proposed a neonatal category for cases whose symptoms were already evident before or at birth, marked by fluid accumulation in the brain and severe intellectual and motor impairment.

Genetic Origins and Cellular Pathology

At its molecular core, Alexander disease is driven by a gain-of-function mutation in the gene encoding glial fibrillary acidic protein, located on chromosome 17q21. The condition follows an autosomal dominant inheritance pattern, meaning a child of a heterozygous affected parent carries a fifty percent chance of inheriting the faulty gene. In practice, however, the majority of diagnosed cases stem from sporadic, de novo mutations rather than familial transmission. The mutated GFAP protein triggers the accumulation of dense, eosinophilic protein clumps called Rosenthal fibers within the cytoplasm of astrocytes, though the precise biochemical pathway behind their formation remains incompletely understood. These fibers are not exclusive to Alexander disease—they also appear in certain cancers, Alzheimer's, Parkinson's, Huntington's, and ALS—but their spatial distribution and concentration in Alexander disease are distinct from those seen in any other condition. The disease primarily targets the midbrain and cerebellum, and the progressive destruction of white matter is compounded by an overload of long-chain fatty acids that further dismantle the myelin sheath insulating nerve fibers.

The Diagnostic Puzzle

Confirming a diagnosis of Alexander disease can be an arduous process, particularly in adult patients whose symptoms overlap with far more common neurological disorders. Magnetic resonance imaging serves as the principal imaging tool, revealing characteristic patterns such as periventricular white matter changes, atrophy of the medulla, and signal abnormalities extending into the spinal cord. Computed tomography scans may additionally show reduced white matter density concentrated in the frontal lobes and dilation of the lateral ventricles. Genetic testing for the underlying GFAP mutation offers a definitive molecular confirmation, while a working clinical diagnosis can sometimes be assembled from the constellation of an enlarged head, progressive neurological decline, and the exclusion of other leukodystrophies through negative laboratory results. Despite these tools, many adults endure years of misdiagnosis—being labeled with multiple sclerosis, Parkinson's disease, or a psychiatric condition—before an MRI finally uncovers the distinctive white matter pathology. The rarity of the disease, affecting roughly one in twenty-seven million individuals, compounds the difficulty, as many clinicians may never encounter a confirmed case in their entire careers.

Prognosis, Rarity, and the Road to Treatment

The outlook for individuals living with Alexander disease remains sobering. Those affected by the infantile form typically succumb before reaching their seventh birthday, with an average survival of roughly three years from onset. The juvenile form carries a somewhat longer trajectory, averaging around six years. A consistent pattern emerges across all presentations: the later the disease manifests, the more gradual its progression. The condition shows no bias by sex, ethnicity, race, geography, or socioeconomic background, striking with equal indifference across all populations. Its extreme rarity—an estimated prevalence of one in 2.7 million—means that even among the many forms of leukodystrophy, it occupies a particularly obscure corner of neurological medicine. Historically, the disease was first described in 1949 by W. Stewart Alexander, who treated a fifteen-month-old infant with an enlarged head, seizures, and developmental delays; over the next fifteen years, only fifteen additional similar cases were recorded before the condition was formally named in his honor. A glimmer of therapeutic hope arrived in September 2026, when the United States approved zilganersen, marketed as Zanvastro, for medical use, marking the first targeted treatment for this devastating disorder.

Gallery